NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company's Share Capital In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorit des Ma

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorit des March s Financiers (French Financial Markets

PARIS--(BUSINESS WIRE)--June 9, 2022--Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Website: www.nanobiotix.com

(1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the

basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order

to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for

humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid

tumors with an initial focus on the treatment of head and neck cancers.

Nanobiotix Communications

Nanobiotix Investor Relations

SVP, Investor Relations

France - Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51